# Dorothy Margolskee

> Dorothy Margolskee is a Series C investor at Foresite Capital backing Medical and Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Foresite Capital](https://shizune.co/investors/profile/foresite-capital)
- Location: Voorhees, United States
- Total investments: 1
- Last investment: Jan 2021
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dorothy-margolskee-3491aa10
- Facebook: https://www.facebook.com/dorothy.margolskee

Dorothy Margolskee is a Series C investor at Foresite Capital in Voorhees focused on Medical and Health Care. Dorothy Margolskee is based out of Voorhees, New Jersey and is the Managing Director of Foresite Capital Management. Dorothy previously worked at Prospect Venture Partners as a Senior Advisor. Dorothy Margolskee attended The Johns Hopkins University School of Medicine. Dorothy has received an MRL Divisional Scientific Award.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Affinivax | Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases.This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existingvaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today.The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform. | $226M | Series C | Jan 08, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 1 deal together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 1 deal together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 1 deal together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 1 deal together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 1 deal together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 1 deal together

## About Foresite Capital

VC Fund · San Francisco, United States

Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.

5 contacts available at Foresite Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dorothy Margolskee | Managing Director | https://shizune.co/investors/profile/dorothy-margolskee |
| James Tananbaum | Founder and CEO | https://shizune.co/investors/profile/jim-tananbaum |
| Stephen C. Peterson | Partner | https://shizune.co/investors/profile/stephen-c-peterson |
| Dennis D. Ryan | CFO & Managing Director | https://shizune.co/investors/profile/dennis-d-ryan |
| Elizabeth Liz Canis | Senior Advisor | https://shizune.co/investors/profile/elizabeth-liz-canis |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Dorothy Margolskee invest in?

Dorothy Margolskee invests primarily in Medical, Health Care and Biotechnology startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dorothy Margolskee last invest?

The most recent investment recorded for Dorothy Margolskee closed in Jan 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co